Real-world candidacy to mavacamten in a contemporary hypertrophic obstructive cardiomyopathy population.
Edoardo BerteroChiara ChitiMaria Alessandra SchiavoGiacomo TiniPaolo CostaGiancarlo TodiereBarbara MabrittoLorenzo-Lupo DeiAlessia GiannattasioDavide MarianiCarla LofiegoCaterina SantolamazzaEmanuele MondaGiovanni QuartaDavide BarbisanGiulia Elena MandoliMassimo MapelliMaurizio SguazzottiFrancesco NegriSimona De VecchiMichele CiabattiDaniela TomasoniAndrea MazzantiFrancesca MarzoCesare de GregorioClaudia RaineriPier Filippo VianelloAlberto MarchiGiulia BiagioniEleonora InsinnaVanda ParisiRaffaello DitarantoAndrea BarisonAndrea GiammarresiGaetano Maria De FerrariSilvia PrioriMarco MetraMaurizio PieroniGiuseppe PattiMassimo ImazioEnrica PeruginiPiergiuseppe AgostoniMatteo CameliMarco MerloGianfranco SinagraMichele SenniGiuseppe LimongelliEnrico AmmiratiFabio VagnarelliLia CrottiLuigi BadanoChiara CaloreDomenico GabrielliFederica ReGiuseppe MusumeciMichele EmdinEmanuele BarbatoBeatrice MusumeciCamillo AutoreElena BiaginiItalo PortoIacopo OlivottoMarco CanepaPublished in: European journal of heart failure (2024)
Real-world HOCM patients differ from the EXPLORER-HCM population for their older age, lower LVEF and larger atrial volume, potentially reflecting a more advanced stage of the disease. About half of real-world HOCM patients were found eligible to mavacamten.